Overcoming mTOR resistance mutations with a new-generation mTOR inhibitorVanessa Rodrik-Outmezguine, Kevan M. Shokat, Zhan Yao et al.|Nature|2016Cited by 483
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous SchedulesSylvie M. Guichard, Sabina Cosulich|Molecular Cancer Therapeutics|2015Cited by 125